Home › Pharmacology › Poorly Absorbed Sulfonamides (Enteric Sulfonamides)

Poorly Absorbed (Enteric) Sulfonamides

For medical students2 min readUpdated 2026-10-10

Enteric sulfonamides are a group of poorly absorbed antimicrobial drugs that achieve high therapeutic concentrations directly within the intestinal lumen. These agents are widely used to treat enteric infections and prevent postoperative complications in gastrointestinal surgery.

AbsorptionPractically non-absorbable from the GI tract

IndicationsEnteric infections and bowel surgery

Key DrugsPhthalylsulfathiazole and sulfaguanidine

Safety ProfileLow toxicity, minimal adverse effects

Pharmacokinetics and Mechanism of Action

The primary pharmacokinetic feature of this group is that the drugs are virtually unabsorbed in the gastrointestinal tract. Consequently, the active substances maintain high concentrations directly within the intestinal lumen, targeting localized pathogens.

Primary Clinical Indications

These pharmacological agents are indicated in the following clinical scenarios:

Enteric infections, including shigellosis, dysentery, enterocolitis, and gastroenteritis.
Prophylaxis of suppurative complications during intestinal surgeries.

Specific Pharmacology of Agents

This group includes specific drugs with unique activation pathways and clinical applications:

Phthalylsulfathiazole: Undergoes chemical cleavage in the small intestine where the phthalic acid moiety is split off, exposing the amino group to release the active compound (sulfathiazole or norsulfazole). It is administered 4–6 times daily and is characterized by low toxicity and practically no adverse effects.
Sulfaguanidine: Completely analogous to phthalylsulfathiazole in its mechanism and pharmacological action.

Combination and Supportive Therapy

Because pathogens may reside not only in the lumen but also within the bowel wall, and can develop resistance, monotherapy is often insufficient.

Combinations: To enhance therapeutic efficacy, it is rational to combine enteric formulations with systemically absorbed sulfonamides (such as sulfaethidole or sulfadimidine).
Supportive care: B-complex vitamins (thiamine, riboflavin, nicotinic acid) must be prescribed concomitantly. This is necessary because sulfonamides suppress the normal flora—specifically Escherichia coli—which is normally responsible for synthesizing these vitamins in the human body.

Frequently asked questions

Which drugs belong to the group of enteric sulfonamides?

Enteric sulfonamides are poorly absorbed drugs that create high concentrations in the intestinal lumen. They include:

Phthalylsulfathiazole — releases phthalic acid and exposes the amino group in the small intestine, forming the active substance (sulfathiazole or norsulfazole).
Sulfaguanidine — analogous in mechanism and action to phthalylsulfathiazole.

What is the mechanism of antibacterial action of sulfonamides at the cellular level?

Sulfonamides exert their antibacterial effect by competitively inhibiting the enzyme dihydropteroate synthase, thus disrupting bacterial intracellular metabolism. Due to their structural similarity to para-aminobenzoic acid (PABA), these drugs act as competitive antagonists. They block the earliest stage of synthesis: the conversion of PABA into dihydropteroate and subsequently dihydrofolate. This prevents the formation of active folic acid derivatives required by the bacterial cell for nucleotide synthesis and proliferation.

What is the antibacterial spectrum of enteric sulfonamides?

The spectrum of enteric sulfonamides includes intestinal infections such as shigellosis, dysentery, enterocolitis, and gastroenteritis. Because pathogens may localize not only within the lumen but also in the intestinal wall, and resistance may develop, combining these agents with well-absorbed sulfonamides (e.g., sulfaethidole or sulfadimidine) increases overall efficacy.

What side effects and complications may occur with prolonged use of enteric sulfonamides?

Phthalylsulfathiazole has low toxicity with virtually no side effects. However, prolonged use of sulfonamides can alter the normal intestinal flora (dysbiosis) and lead to hypovitaminosis due to the suppression of Escherichia coli, which participates in the synthesis of B vitamins (thiamine, riboflavin, and nicotinic acid). Therefore, B-complex vitamin supplementation is mandatory.

Why do enteric sulfonamides achieve high concentrations specifically in the intestinal lumen?

Because these drugs possess the property of being virtually unabsorbed in the gastrointestinal tract.

Why are B-complex vitamins routinely prescribed during treatment with enteric sulfonamides?

The drugs suppress Escherichia coli, which normally synthesizes B-complex vitamins in the body, necessitating exogenous supplementation.

How is phthalylsulfathiazole activated in the body?

In the small intestine, the phthalic acid molecule is cleaved off, releasing the amino group and forming the active substance sulfathiazole (norsulfazole).

Go deeper

Molecular mechanism of phthalylsulfathiazole activation
Regimens for combining enteric and systemic sulfonamides
The role of Escherichia coli in B-complex vitamin synthesis
Prophylaxis of intestinal surgical complications using sulfonamides